<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03891875</url>
  </required_header>
  <id_info>
    <org_study_id>SPIAM-202</org_study_id>
    <nct_id>NCT03891875</nct_id>
  </id_info>
  <brief_title>ReCLAIM-2 Study to Evaluate Safety,Efficacy &amp; Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA</brief_title>
  <acronym>ReCLAIM-2</acronym>
  <official_title>A Phase 2 Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Elamipretide in Subjects With Age-Related Macular Degeneration With Non-central Geographic Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stealth BioTherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stealth BioTherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-masked, placebo controlled study to evaluate the safety, efficacy and&#xD;
      pharmacokinetics of elamipretide in subjects with Age-Related Macular Degeneration with&#xD;
      non-central Geographic Atrophy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of elamipretide in looking at the change in low-luminance best-corrected visual acuity</measure>
    <time_frame>Baseline to week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of elamipretide through change in low-luminance ready acuity</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of elamipretide through best-corrected visual acuity</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of elamipretide through the change in GA area as measured by fundus autofluorescence</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of elamipretide through the change in GA area as measured by optical coherence tomography</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Elamipretide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg subcutaneous injection of elamipretide using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous injection of placebo using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Subcutaneous elamipretide through the elamipretide delivery system</intervention_name>
    <description>Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.</description>
    <arm_group_label>Elamipretide</arm_group_label>
    <other_name>elamipretide</other_name>
    <other_name>MTP-131</other_name>
    <other_name>Bendavia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Subcutaneos placebo through the elamipretide delivery system</intervention_name>
    <description>Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 55 years of age with at least 1 eye with AMD with non-central GA as&#xD;
             determined by FAF.&#xD;
&#xD;
        Ocular conditions-study eye&#xD;
&#xD;
          -  GA in the study eye at the Screening Visit may be multi-focal, but the cumulative GA&#xD;
             lesion and size must:&#xD;
&#xD;
               1. be ≥ 0.05 mm2 and ≤ 10.16 mm2 and&#xD;
&#xD;
               2. reside completely within the FAF 30 or 35 degree image.&#xD;
&#xD;
               3. must be at least 150 μm from foveal center with preserved outer retinal&#xD;
                  structural details&#xD;
&#xD;
          -  No evidence of CNV by history, OCT or FA in the study eye.&#xD;
&#xD;
          -  BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) score of ≥ 55 letters&#xD;
             (Snellen equivalent ≥ 20/70) in the study eye at the Screening Visit and Baseline&#xD;
             Visit.&#xD;
&#xD;
          -  LL BCVA by ETDRS score of ≥ 10 letters in the study eye at the Screening Visit and&#xD;
             Baseline Visit.&#xD;
&#xD;
          -  LL VA deficit (defined as difference the between BCVA and LL BCVA) of &gt; 5 letters in&#xD;
             the study eye at Screening and Baseline Visits.&#xD;
&#xD;
          -  The fellow eye may have any of the following: no AMD, AMD without GA, AMD with GA, CNV&#xD;
             AMD, or central GA. Ongoing treatment with anti-angiogenic therapies in the fellow eye&#xD;
             is allowable.&#xD;
&#xD;
          -  Sufficiently clear ocular media, adequate pupillary dilation, fixation to permit&#xD;
             quality fundus imaging, and ability to cooperate sufficiently for adequate ophthalmic&#xD;
             visual function testing and anatomic assessment in the study eye.&#xD;
&#xD;
        Systemic and general criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ocular conditions-study eye&#xD;
&#xD;
          -  The absence of observable hyper-FAF at the margins of the GA in the study eye(only for&#xD;
             lesions ≥ 0.25mm2)&#xD;
&#xD;
          -  Atrophic retinal disease of causality other than AMD including myopia-related&#xD;
             maculopathy and monogenetic macular dystrophies including pattern dystrophy and&#xD;
             adult-onset Stargardt disease in the study eye.&#xD;
&#xD;
          -  Presence or diagnosis of exudative AMD or CNV in the study eye.&#xD;
&#xD;
          -  Presence of retinal vein occlusion in the study eye.&#xD;
&#xD;
          -  Presence of diabetic retinopathy (a history of diabetes mellitus without retinopathy&#xD;
             is not a criterion for exclusion) in either eye.&#xD;
&#xD;
          -  Presence of vitreous hemorrhage in the study eye.&#xD;
&#xD;
          -  History of retinal detachment in the study eye.&#xD;
&#xD;
          -  History of macular hole (stages 2 to 4) in the study eye.&#xD;
&#xD;
          -  Presence of an epiretinal membrane that causes distortion of the retinal contour in&#xD;
             the study eye.&#xD;
&#xD;
          -  Presence of vitreomacular traction in the study eye.&#xD;
&#xD;
          -  At the Screening Visit, advanced glaucoma resulting in a cup to disc ratio of &gt; 0.8 in&#xD;
             the study eye.&#xD;
&#xD;
          -  History of glaucoma filtration surgery or uncontrolled glaucoma defined as IOP &gt; 22&#xD;
             mmHg at baseline despite anti-glaucoma treatment with or without topical&#xD;
             anti-hypertensive eye drops in the study eye OR currently using &gt; 2 medications (note:&#xD;
             combination medications count as 2 medications).&#xD;
&#xD;
          -  Presence of visually significant cataract OR presence of significant posterior&#xD;
             capsular opacity in the setting of pseudophakia. Significant cataract is defined as &gt;&#xD;
             +2 nuclear sclerosis based upon the scale below or any Posterior Subcapsular Cataract&#xD;
             in the study eye. The Sponsor, or its designee, will supply the trial sites with a&#xD;
             copy of the standard photographs.&#xD;
&#xD;
          -  Presence of significant keratopathy or any other media or corneal opacity that would&#xD;
             cause scattering of light or alter visual function, especially in LL conditions in the&#xD;
             study eye.&#xD;
&#xD;
          -  Ocular incisional or laser surgery (including cataract surgery) in the study eye&#xD;
             within 90 days before Day 1.&#xD;
&#xD;
          -  Yag laser capsulotomy in the study eye within 30 days before Day 1.&#xD;
&#xD;
          -  Aphakia in the study eye.&#xD;
&#xD;
          -  History of vitrectomy surgery, submacular surgery, or any vitreoretinal surgery in the&#xD;
             study eye.&#xD;
&#xD;
          -  Prior treatment with Visudyne® (verteporfin) ocular photodynamic therapy,&#xD;
             external-beam radiation therapy (for intraocular conditions), or transpupillary&#xD;
             thermotherapy in the study eye.&#xD;
&#xD;
          -  History of subthreshold laser treatment or other forms of photobiomodulation for AMD&#xD;
             in the study eye.&#xD;
&#xD;
          -  Intravitreal drug delivery in the past 60 days or 5-half-lives of the injected drug&#xD;
             whichever is longer (e.g., intravitreal corticosteroid injection, anti angiogenic&#xD;
             drugs, or device implantation) in the study eye.&#xD;
&#xD;
          -  Current use of medications known to be toxic to the lens, retina, or optic nerve&#xD;
             (e.g., deferoxamine, chloroquine/hydroxychloroquine [Plaquenil®], tamoxifen,&#xD;
             phenothiazines, ethambutol, digoxin, and aminoglycosides) from the Screening Visit&#xD;
             through the completion of the trial.&#xD;
&#xD;
        Ocular conditions--either eye&#xD;
&#xD;
          -  History of herpetic infection in either eye.&#xD;
&#xD;
          -  Concurrent disease in either the study eye or fellow control eye that could require&#xD;
             medical or surgical intervention during the study period.&#xD;
&#xD;
          -  Active uveitis and/or vitritis (grade trace or above) in either eye.&#xD;
&#xD;
          -  History of idiopathic or autoimmune-associated uveitis in either eye.&#xD;
&#xD;
          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either&#xD;
             eye.&#xD;
&#xD;
        Systemic conditions.&#xD;
&#xD;
          -  Known to be immunocompromised or receiving systemic immunosuppression for ≥ 4&#xD;
             consecutive weeks prior to screening.&#xD;
&#xD;
          -  Any disease or medical condition that in the opinion of the Investigator would prevent&#xD;
             the subject from successfully participating in the study or might confound study&#xD;
             results.&#xD;
&#xD;
        General&#xD;
&#xD;
          -  Participation in other investigational drug or device clinical studies within 30 days&#xD;
             of enrollment and/or planning to participate in any other investigational drug or&#xD;
             device clinical studies within 30 days of study completion.&#xD;
&#xD;
          -  History of allergy to fluorescein that is not amenable to treatment.&#xD;
&#xD;
          -  Creatinine clearance of ≤ 30 mL/min at the Screening Visit (using Modification of Diet&#xD;
             in Renal Disease Study formula).&#xD;
&#xD;
          -  Inability to comply with study or follow-up procedures.&#xD;
&#xD;
          -  Inability to obtain color fundus photograph, FAF, and FA of sufficient quality to be&#xD;
             analyzed and interpreted.&#xD;
&#xD;
          -  Active malignancy or any other cancer from which the subject has been cancer-free for&#xD;
             &lt; 2 years.&#xD;
&#xD;
          -  History of allergic reaction to the investigational drug or any of its components.&#xD;
&#xD;
          -  Prior treatment with Elamipretide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sathyanarayana</last_name>
    <role>Study Director</role>
    <affiliation>Stealth BioTherapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Associated Retina Consultants, Ltd.</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Research Institute, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Retina &amp; Vitreous Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Research Institute, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Retina Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Institute of California Medical Group</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedEye Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Retina and Macular Disease</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center, PC</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Care Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland valley retina consultants</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Retina Consultants</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialty Eye Institute</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Center of New Jersey LLC</name>
      <address>
        <city>Bloomfield</city>
        <state>New Jersey</state>
        <zip>07003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Retina</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Western New York</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Eye center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Northwest, P.C</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Retina</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute of Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Center, PLLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute, PA</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia, Department of Ophthalmology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Macular degeneration</keyword>
  <keyword>non-central geographic atrophy</keyword>
  <keyword>MTP-131</keyword>
  <keyword>elamipretide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

